CJC1295 No DAC (other name is MOD-GRF (1-29)) +Ipamorelin - Educational material

CJC-1295 and ipamorelin are synthetic peptides studied in connection with the regulation of growth hormone release. However, they are not the same substance, do not have an identical structure and do not interact with the same receptor. Additional confusion is caused by the name „CJC-1295 without DAC”, often referred to as MOD-GRF (1–29). Before comparing publications, it is necessary to determine which structure is actually being described.

The most important distinction concerns three entities: a GHRH analogue equipped with an albumin-binding moiety, a modified GHRH fragment without this moiety, and a separate pentapeptide, which is ipamorelin. The simultaneous appearance of these names in articles does not mean that the results concerning one compound are the results concerning the others.

This guide covers nomenclature, sequences, and basic biological context. It also explains how to interpret hormone release studies and why they are not automatically evidence of broad health benefits. It is not a guide on combining or using peptides.

What do the names in this article mean?

CJC-1295 is the designation for a compound described in initial research as a long-acting analogue of human growth hormone-releasing factor. Its design includes an element enabling binding to albumin. This characteristic is important for the identity and interpretation of research. Source: Jetté et al., 2005.

MOD-GRF (1–29) is a term for a modified, 29-residue fragment of GHRH. It is also known in circulation as „CJC-1295 no DAC”. However, one should not on this basis treat every text containing the abbreviation CJC-1295 as a description of this shorter structure without the DAC element.

Ipamorelin, in English literature ipamorelin, is a separate peptide. Its name does not mean a part of CJC-1295 or a component that must be combined with it. Each of these compounds can be described separately.

Throughout this article, the term „CJC-1295 with DAC” refers to the structure containing the albumin-binding element. The term „MOD-GRF (1–29)” is used to describe the 29-residue analogue without this element. This notation helps to avoid the ambiguities found in popular texts.

A brief comparison of three structures

A common biological theme is the release of growth hormone. The structure and method of initiating the receptor response remain different.

Name	Basic description	The most important distinguishing feature
MOD-GRF (1–29)	A 29-residue modified GHRH fragment	Four substitutions in the sequence; absence of the albumin-binding element characteristic of DAC
CJC-1295 with DAC	An analogue based on a modified GHRH(1–29) with an additional structural element	Ability to bind to albumin
Ipamorelin	Synthetic pentapeptide	A different sequence and interaction with the ghrelin receptor (GHS-R1a)

The table describes identity and classification. It is neither a ranking of efficacy nor of safety. Nor does it allow one to determine how any given mixture of these substances will behave.

It is worth noting that a short name may omit a very important detail. The DAC suffix is not merely information about convenience or the expected duration of action. It refers to a specific chemical modification. Similarly, the word ‘pentapeptide’ indicates the number of ipamorelin residues, but does not in itself describe its full activity.

GHRH and GRF — where do these abbreviations come from?

GHRH stands for growth hormone-releasing hormone. The term GRF, which stands for growth hormone-releasing factor, also appears in the literature. In the context discussed, these names refer to a signal involved in the regulation of GH secretion.

In the Polish language, the name somatoliberin can be encountered. Different spellings do not mean that each article describes a different hormonal system. However, one must pay attention to additional designations of fragments and analogues, as these may already indicate distinct structures.

The notation GHRH(1–29) refers to the section comprising residues one to twenty-nine. The numbers do not indicate the amount of material, the frequency of use or the duration of observation. They form part of the sequence information.

MOD, derived from the word ‘modified’, indicates a modification. Therefore, MOD-GRF (1–29) should not be interpreted as just any unmodified fragment of the natural hormone. The abbreviation itself requires further clarification as to what changes have been made and whether the full description also includes the chain termini.

GH and IGF-1 are not the names of these peptides

GH is the abbreviation for the English name of growth hormone. IGF-1 stands for insulin-like growth factor 1. These molecules appear in publications about CJC-1295 and ipamorelin because researchers are analysing the endocrine system's response.

However, CJC-1295 should not be called a „synthetic growth hormone”. It is a signalling analogue acting at an earlier stage of regulation. Ipamorelin is also not GH. It belongs to compounds capable of inducing its release through a different receptor mechanism.

Put simply, the signal, the hormonal response and the subsequent biological consequences can be separated. They are connected, but measuring one element does not automatically represent all the others.

Therefore, information about an increase in GH or IGF-1 concentration should remain information about that parameter alone. It is not an independent measurement of strength, fitness, sleep quality, or the rate of ageing. Such results would require studies specifically designed to assess them. Basic knowledge of the role of hormones does not replace findings concerning a specific compound.

What does the word peptide mean?

A peptide is a molecule containing linked amino acid residues. It is not a loose mixture of amino acids. Their order, manner of connection and additional chemical characteristics matter.

MOD-GRF (1–29) contains significantly more residues than ipamorelin. This difference allows the chain length to be described, but it is not a direct measure of potency. A shorter peptide does not have to be weaker, and a longer one is not automatically more selective.

Nor does the word peptide constitute a safety assessment. It encompasses a wide group of compounds with very different properties. The body's natural peptides and synthetic analogues may share certain structural features, but identical behaviour should not be assumed.

In the case of the substances in question, a more precise description requires information on their sequence and modifications. Only this information indicates which compound is being studied. The term „growth hormone peptides” alone encompasses a variety of structures and is not sufficient for comparing their results.

How is MOD-GRF (1–29) structured?

MOD-GRF (1–29) is an analogue of the GHRH fragment with substitutions at positions 2, 8, 15 and 27. Its sequence can be written as follows:

H–Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Gln–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Leu–Ser–Arg–NH₂

The sequence contains 29 residues. Two consecutive leucines are found at positions 22 and 23. Omitting one of them alters the sequence; it is not an abbreviated version of the correct sequence. The characteristics of this structure are described in the 2024 FDA document concerning compounds known as CJC-1295. Source: FDA, chemical characteristics.

The reader does not need to memorise the entire sequence. What is more important is to understand that the sequence is an ordered description of a single molecule. Its parts are not a list of components that can be rearranged at will. The additional designations D and NH₂ have structural significance and should not be omitted when comparing analogues.

Four substitutions relative to the natural GHRH fragment

The term tetrasubstituted analogue means modifications at four positions of the sequence. It does not mean four additional amino acids attached to the end of the chain.

Position	The rest is found in a fragment of human GHRH	The rest in MOD-GRF (1–29)
2	Wing	D-Ala
8	Asn	Gln
15	Gly	Wing
27	Met	Leu

The table shows that the modification can consist of both changing the type of residue and its spatial configuration. D-Ala remains an alanine in terms of the basic amino acid type, but its configuration differs from the standard L-alanine at this position in the natural sequence.

Such a comparison helps to understand the concept of an analogue without ranking the compounds. Introducing substitutions does not automatically improve all properties. The impact of a change on recognition by enzymes or receptors, or on behaviour in solution, requires appropriate data. The table itself illustrates the structure, not a comprehensive assessment of biological effects.

What do the N- and C-termini mean?

A peptide sequence is usually presented from the amino end, referred to as N, to the carboxyl end, referred to as C. The direction is part of an established convention. It does not describe the movement of the molecule within the organism.

In the notation MOD-GRF (1–29), the letter H before the first residue is not an additional amino acid. Conversely, the NH₂ at the end indicates an amidated chain termination. A similar designation appears in the ipamorelin sequence.

Information about the terminal groups is important because the amino acid sequence alone does not always describe all the characteristics of a peptide. Two compounds may have a similar amino acid sequence but differ in the modification of the terminal group or a side chain.

Therefore, when checking identity, the whole record must be read, and not just its middle part. The disappearance of an amide suffix or a DAC element may mean missing a feature that distinguishes the studied structures. In the introductory article, it is enough to clearly explain the role of these designations, without going into synthesis instructions.

What does DAC stand for in the name CJC-1295?

DAC stands for Drug Affinity Complex. With regard to CJC-1295, it refers to a structural element enabling binding to albumin. The initial description outlines an additional, modified lysine residue at the C-terminus of the GHRH(1–29) analogue. Source: Jetté et al., 2005.

This is not an ordinary solvent, preservative, or loosely added ingredient of the mixture. The note refers to the structure of the compound prior to forming a bond with the protein.

This is an important distinction when reading publications. If a structure containing such an element was studied, the result cannot be directly applied without modification to the description of a structure that does not contain it. A shared peptide part does not imply complete chemical equivalence.

DAC should also not be translated as the general label „more stable peptide”. Stability can refer to various processes, and this abbreviation points to a specific structural solution. Only appropriate studies describe how it affects a given parameter in a chosen system.

Albumin and peptide conjugate

Albumin is a protein present in plasma. CJC-1295 studies have utilised the ability to bind a reactive analogue fragment to the thiol group of a cysteine residue in albumin, designated as Cys34. Such a peptide-protein compound is called a bioconjugate. Source: Jetté et al., 2005.

For the non-specialist, the difference between the mere presence of two components and their chemical combination is significant. A peptide located next to a protein in a solution and a peptide attached to a protein are not identical situations.

This also does not mean that CJC-1295 itself is an albumin. A distinction must be made between the pre-binding analogue, the albumin, and the resulting conjugate. Each of these entities has a different scope of description.

The binding mechanism helps to understand interest in the circulation time of the analogue. However, it is not proof of all subsequent hormonal or tissue effects. Evaluating exposure to a substance and evaluating a specific biological result remain separate research tasks.

Why does „no DAC” not mean „the same, only shorter”?

The description „the same, just shorter” glosses over the change in structural identity and the course of the exposure. The difference does not boil down to rearranging a single number in the reaction time table.

In the case of CJC-1295, it must be established whether the material has an albumin-binding moiety, and also whether the free form, the protein-bound form, or a specific salt form was analysed. A result concerning one of these situations is not a complete description of the others.

It is possible to formulate hypotheses based on structural similarities. However, a hypothesis remains something different from a direct comparison. If no study has been conducted demonstrating a specific result for MOD-GRF (1–29), this gap should not be replaced by the result for CJC-1295 with DAC.

This distinction applies to both efficacy and safety. Shorter exposure does not automatically prove the absence of a specific risk. Longer exposure also does not in itself imply a greater benefit. Every such claim requires naming the parameter being assessed and indicating the relevant data.

What is ipamorelin?

Ipamorelin is a synthetic pentapeptide, which means a peptide containing five amino acid residues. Its sequence is:

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

In the original 1998 paper by Raun and co-workers, it was described as a selective growth hormone secretagogue. The word secretagogue means a substance that promotes secretion. Source: Raun et al., 1998.

Ipamorelin is not a fragment of CJC-1295. Nor is it formed automatically by removing DAC. Its short chain has a different composition and should be analysed as a separate structure.

It is worth distinguishing chemical nomenclature from terms such as „third generation”. Such a label does not present a sequence or establish a uniform ranking of all peptides. In a general article, specific information about the number of residues, structure and receptor is more useful than an unexplained suggestion that the next generation of a compound universally means better properties.

How to read unusual abbreviations in an ipamorelin sequence?

His, Phe and Lys stand for histidine, phenylalanine and lysine respectively. Aib refers to alpha-aminoisobutyric acid, and 2-Nal to 2-naphthylalanine. Aib and Nal do not belong to the standard set of residues used in routine protein synthesis according to the genetic code. Source: FDA, characteristics of ipamorelin.

The term „non-protein amino acid” describes a chemical classification. It is not a standalone statement about harmfulness or a particular benefit. Nor does it mean that a given element ceases to be part of a peptide structure.

In the sequence, the D-labels at the corresponding residues must be retained. Removing them simplifies the notation at the cost of important spatial information. Similarly, the number 2 in 2-Nal is not the number of amino acid repeats in the chain.

For the reader, the most important thing is to recognise that the five residues do not represent five entirely ordinary, interchangeable components. The full identity of ipamorelin depends on the specific residues, their sequence and configuration.

What do the designations D and L mean?

The D and L designations refer to the spatial configuration of specific amino acids. Simply put, they can describe two mirror-image forms. In biological systems, such a difference can be significant for molecule recognition.

In MOD-GRF (1–29), D-alanine at the second position is essential. In ipamorelin, the notation indicates D-2-Nal and D-Phe, among others. These designations are neither decoration of the name nor a unit of quantity.

The letter D should not be equated with the single-letter code for aspartic acid when it appears as a prefix in the notation D-Ala. In these two situations, the similar symbol performs a different function. The context of the notation determines its meaning.

Stereochemistry is one of the reasons why mass matching is not sufficient to fully confirm identity. Two forms can have the same elemental composition, but differently arranged atoms. When comparing the peptides in question, it is therefore also necessary to take into account information that the empirical formula alone does not show.

Molecular formulae and molar masses

For the defined, 29-residue structure without DAC, C₁₅₂H₂₅₂N₄₄O₄₂ and a molar mass of approximately 3368 g/mol are given. For ipamorelin, these are C₃₈H₄₉N₉O₅ and approximately 711.9 g/mol. These are parameters of the chemical units, without the automatic addition of counterions and other material components. Source: FDA — CJC-1295, FDA — ipamorelin.

The first formula should not be attributed to all structures described by the abbreviation CJC-1295. The addition of the DAC element changes the composition of the molecule. The binding to albumin creates yet another entity than the free analogue itself.

The molar mass is neither the weight of the packaging nor the amount of peptide in any given sample. It is a parameter resulting from the composition of a specific substance. A sample may also contain water, counter-ions and other components.

Therefore, when reading tables, it is worth checking what the numbers refer to. A common name in the header does not eliminate the differences between the peptide itself, its salt, conjugate, and mixture. A single formula does not correctly describe all these situations.

An acetate post is not a component of the DAC

In material names, you can encounter CJC-1295 acetate or ipamorelin acetate. The reference to acetate relates to the salt form. It does not indicate an additional amino acid in the sequence or an element enabling albumin binding.

This is particularly important for CJC-1295, as two different types of information may appear in a single description: the presence of DAC and the acetate form. They should not be combined into a single modification category.

It is also worth checking whether the numerical data refer to the peptide moiety alone or to the entire material. The general description of the salt form does not always state the full proportion of all components of the sample.

For a reader without a chemical background, it is helpful to separate three questions: what the sequence is, what has been chemically attached to the peptide, and what additional ingredients the material includes. Each question concerns a different level of description. The name of the acetate does not replace the answers to the other two.

GHRH receptor and ghrelin receptor

GHRH analogues and ipamorelin are discussed in relation to the same hormone, but initiate a response via different receptors. For GHRH analogues, the reference point is the GHRH receptor. Ipamorelin is described as an agonist of the ghrelin receptor, also known as GHS-R1a. Source: Jetté et al., 2005, Beck et al., 2014.

A receptor can be understood as a structure that receives a specific signal. The word agonist means a compound capable of activating a given receptor. It is not a synonym for growth hormone or a general assessment of clinical efficacy.

This receptor difference explains why researchers may be interested in the connections between these pathways. It does not prove, however, that any combination of substances will yield a specific result.

Nor should one conclude from it that all subsequent processes are completely independent of each other. The endocrine system involves interconnected mechanisms. A correct description preserves the distinction between receptors while at the same time not presenting them as two simple buttons guaranteeing an arbitrarily chosen response.

Why is ipamorelin not ghrelin?

Ghrelin is a naturally occurring peptide, the receptor of which is the point of reference in the description of ipamorelin. The agonist of this receptor does not have to be structurally identical to ghrelin. A common receptor target does not imply a common sequence.

Similarly, the term „ghrelin mimetic” indicates the reproduction of a selected type of signal rather than full equivalence of all properties. One should not on this basis attribute every process discussed in texts concerning the natural hormone to ipamorelin.

Various agonists of the same receptor may appear in publications. The result for one of them is not automatically the result for another. Structural differences and study conditions still matter.

For a general comparison, it is therefore sufficient to say that ipamorelin belongs to a specific class of compounds and has its own defined structure. Classification helps to organise the literature, but it does not replace data concerning a specific molecule. It is a map of similarities, not a list of freely interchangeable substances.

What does the selectivity of ipamorelin mean?

Selectivity describes the relative preference of a specific action compared to other responses. In the original work on ipamorelin, the release of GH and selected other hormones was evaluated in the models used. This is where the meaning of the term comes from in this context. Source: Raun et al., 1998.

This result should not be turned into the sentence „ipamorelin never affects any other hormone”. This would be a much broader claim than the scope of the specific experiment. Furthermore, selectivity does not imply the absence of all adverse effects.

Each study covers specific parameters, a model and conditions. A lack of demonstrated response in a single measurement is not a complete description of the compound's behaviour throughout the whole organism.

It is therefore worth keeping the word selectivity in the article, but explaining it without the promise of safety. It is a property assessed relative to named points of reference. It is not a certificate of universal neutrality towards all other biological processes.

Secretion, production and cell count

Hormone secretion means its release from cells. Production refers to manufacture, and the number of cells defines yet another characteristic of the tissue. These concepts are sometimes used interchangeably in popular descriptions, although they do not represent the same thing.

If more GH was measured in the blood after a specific stimulus, it does not mean in itself that pituitary cells have increased. Nor does it prove that their number of secretory granules has increased or that all stages of hormone synthesis have been examined.

Different methods are needed to assess these issues. Hormone measurement, microscopic examination and gene activity analysis answer different questions.

With regard to CJC-1295 and ipamorelin, one should therefore avoid the simplistic division according to which one peptide „increases the pulse” and the other „increases cell count”. Such a pair of slogans is not a sufficient description of the mechanism nor the result of a direct study of the combination. A better description points to the receptor and the parameter actually evaluated.

What does pulsatile GH secretion mean?

Pulsatility means that secretion changes over time, instead of maintaining a constant value. In the analysis, one can consider the frequency of the pulses, their amplitude and the baseline level between them.

The study by Ionescu and Frohman on CJC-1295 merely analysed the pattern of GH secretion during prolonged stimulation. It was not a study proving that all characteristics of the system remained identical to those prior to exposure. Source: Ionescu and Frohman, 2006.

Preserving recognisable pulses does not mean an unchanged hormonal profile. It can coexist with a change in the level between pulses or of other parameters. Therefore, the term „natural rhythm” is too general if it replaces a detailed description of the result.

A single GH measurement should also not be treated as a full assessment of pulsatility. A series of data is needed to describe changes over time. A single value may fall at a different point in the course and does not represent the entire pattern. This is the fundamental difference between an instantaneous concentration and a secretion analysis.

Hormone concentration and total response over time

Concentration describes the amount of substance in a specific volume. In hormone research, the area under the curve, often abbreviated as AUC, can also be analysed. Such an indicator summarises the course of concentration over a defined time interval.

The temporary peak, mean concentration and AUC are not identical parameters. When a publication on CJC-1295 reports a fold change in one of them, the name of the measurement must be retained. It cannot be converted into the 24-hour amount of hormone produced without additional data.

Similarly, the increase in level between pulses is not automatically equal to the increase of each pulse. Depending on the method, authors may describe different parts of the same response.

For the reader, the question „what exactly increased?” is important. It helps avoid the mistake where an effect expressed as a multiple of one indicator is presented as an equal multiplication of all processes related to GH. A number without the name of the parameter may sound impressive, but convey little useful information.

What was actually evaluated in human studies of CJC-1295?

Teichman and colleagues in 2006 described studies in healthy adults evaluating, among other things, GH and IGF-1 concentrations and the duration of the response. The results concerned the long-acting analogue CJC-1295. Source: Teichman et al., 2006.

This is significant evidence of a hormonal response, but not a complete test of all the endpoints associated with this peptide. Measuring concentrations is not at the same time a study of strength, sleep quality, memory, skin appearance and lifespan.

The results of this work should also not be extrapolated to the mixture of MOD-GRF (1–29) with ipamorelin. That would be a different subject of study. A known response to one component does not replace a direct assessment of two components together.

A reliable description therefore preserves the value of the data obtained while simultaneously respecting its limits. One could say that the hormonal response in specific participants was analysed. There is no need to expand this into an assurance of numerous benefits that the project did not evaluate.

What was studied in humans in the case of ipamorelin?

In the 1999 paper by Gobburu et al., the pharmacokinetics and pharmacodynamics of ipamorelin in volunteers were analysed. Such a study combines the description of substance concentration over time with the assessment of biological response. Source: Gobburu et al., 1999.

This kind of project should not be equated with a long-term assessment of fitness or healthy ageing. Even a well-described concentration profile does not answer all clinical questions.

Other studies may involve different populations and objectives. The word „people” alone in a publication's description is too general to combine them into a single conclusion. Healthy volunteers and post-operative patients do not constitute an identical research context.

Therefore, when describing ipamorelin, it is worth stating whether GH release, concentration parameters or a specific clinical outcome was assessed. This makes it possible to understand the research body of work without creating the impression that every publication confirms all the properties attributed to the substance in popular texts.

Why does a Phase II trial not always confirm efficacy?

The trial phase describes the stage of project development, not its positive outcome. A Phase II trial can end without demonstrating superiority over the comparator.

In the work by Beck and colleagues concerning ipamorelin in patients after bowel resection, no significant differences were demonstrated in the primary and secondary efficacy analyses. The numerical difference in the time to tolerate a meal had a p-value of 0.15. It should not be presented as confirmation of effectively accelerating recovery. Source: Beck et al., 2014.

A distinction must also be made between events occurring during the study and events considered to be caused by the study substance. The mere presence of an event after the start of observation does not establish a causal relationship.

This example is important for the entire article: the subject of the publication is not its conclusion. A title reporting on the study of a specific application does not mean that the application has been confirmed. The result must be read from the analysis, while maintaining its scope and limitations.

Animal testing is not a description of effects in all humans

Animal models make it possible to ask questions that cannot be studied in the same way under other conditions. They can relate to specific tissue, hormonal changes or the consequences of a deliberately introduced disorder.

At the same time, the result obtained in a rat, mouse, ferret or fish remains a result for that model. It should not be turned into a statement about human fitness, fertility or metabolism without additional data.

In the case of CJC-1295 and ipamorelin, the baseline state of the model is also important. An organism with a specific disorder is not a simple equivalent of a healthy person interested in general performance enhancement.

A reliable description does not have to omit preclinical studies. It should, however, retain the name of the model and the evaluated parameter. Studying a tissue fragment is yet another level than observing the whole animal. Such distinctions make it possible to appreciate the significance of the experiment without attributing to it answers it could not provide.

A mixture is not a new name for a single peptide

The notation „CJC-1295 + ipamorelin” usually indicates two components. It is not a single peptide sequence nor proof that the components have been chemically bonded.

It is also necessary to determine what CJC-1295 means in such a description. The presence or absence of DAC remains important, even when ipamorelin is listed alongside it. The name of the mixture does not resolve the ambiguity of the first ingredient.

Studying a single peptide does not describe the entire mixture. Similarly, two publications, each concerning a different substance, do not automatically constitute a joint study of the combination.

It is helpful for the reader to separate the identity of the components from the properties of the system as a whole. One can know the sequence of both substances and still lack data concerning their combined response under specific conditions. This is simply a limit of inference, rather than a statement that the mixture cannot by definition have activity.

What does synergy mean and what does demonstrating it require?

Synergy is a specific type of cooperation. In order to evaluate it, one must indicate the measured parameter and the method for determining what response was expected from the components used separately.

The mere information that two compounds act on different receptors does not prove synergy. Neither is the observation sufficient that both affect GH separately. Appropriately designed data on the components and their combination are required for comparison.

Even demonstrated synergy in a single measurement would not automatically establish synergy of all results. The interaction concerning hormone concentration is not direct proof of an additional benefit for memory, skin or physical performance.

Therefore, in the description of CJC-1295 and ipamorelin, it is worth avoiding the use of the word synergy as a synonym for an attractive combination. It can mean a hypothesis requiring testing or the result of a specific experiment. These two meanings should be kept clearly separate.

Pharmacokinetics is not an instruction for use

Pharmacokinetics describes the presence of a substance in the organism over time. Pharmacodynamics concerns the response to that substance. The half-life of a peptide and the duration of change of a selected hormone do not have to mean the same thing.

With regard to the compounds in question, it is particularly important to check the structure, model and method of measurement. Data obtained for CJC-1295 with DAC should not be attributed to MOD-GRF (1–29). The ipamorelin parameter in one study is not a universal value for all conditions.

The presence of the unchanged peptide in excretions should also not be treated as proof of therapeutic benefit. Such a result describes a specific aspect of the substance's disposition.

An article on the basics can explain these concepts without creating a dosing schedule. A figure from a pharmacokinetic publication does not automatically become a recommendation for the timing, frequency or method of using a substance. This is research data that requires proper context to be maintained.

Why doesn't a shorter presence time prove greater security?

Safety does not depend solely on the duration of the substance's presence. Among other things, the nature of the response, the studied population, and the material properties can be significant. The mere information about a shorter half-life does not resolve these issues.

Therefore, MOD-GRF (1–29) should not be presented as automatically safer than CJC-1295 with DAC. Nor is there any basis for deducing from the short exposure any assurances of a lack of insulin resistance or unchanged insulin sensitivity.

Similarly, the term „pulsatile” is not a synonym for safe. It describes the release profile, not a complete risk assessment. The system can maintain pulses while simultaneously changing other parameters.

Clear text should avoid such mental shortcuts. The differences in structure and course of the response can be presented, leaving the safety assessment as a separate question. To resolve it, data is needed, rather than solely a biologically sounding explanation.

What does the lack of serious events in a small study mean?

Early testing can provide important information about tolerance under specific conditions. However, it does not automatically cover rare events, long-term observation or all possible groups of people.

No serious adverse events were reported in the work by Teichman and colleagues. This limited finding is not equivalent to proving the universal safety of CJC-1295, its variants or mixtures. Source: Teichman et al., 2006.

A distinction must be maintained between what has not been observed and what has been ruled out. Failure to detect a problem may be due to the limited sample size or duration of the study, rather than a proven impossibility of its occurrence.

Similarly, the unchanged appearance of cells in a selected experiment is not a full safety assessment of the entire organism. The microscopic result describes a specific material and method. It should not be extended into an assurance that all gland functions or all hormonal processes remain intact.

Internet source versus research publication

In texts about CJC-1295 and ipamorelin, scientific publications, official documents, commercial websites and user accounts appear. They do not serve the same function.

A wellbeing report may describe the author's experience, but it is not a controlled measurement of a substance's effect. The analysis of online discussions can examine the way peptides are spoken about, rather than their biological efficacy.

Similarly, a document placed in a public register may be a submission by an interested party, an opinion or a study by an authority. The place of publication is not sufficient to establish the authorship and status of the content.

That is why it is worth checking who prepared the source, what it investigates and what data it presents. A link next to a sentence does not guarantee that the source actually supports that sentence. In the case of the peptides discussed, this is of particular importance for claims about the combination: a text about a different GHRP is not a direct study of a mixture with ipamorelin.

Sample documentation versus molecule knowledge

Sequence familiarity defines the reference structure. However, it does not confirm that every sample described by the name CJC-1295 or ipamorelin has precisely this identity.

Analytical documentation may contain identification, purity, and assay results. These parameters are not interchangeable. Identity refers to the recognition of a compound, and assay to the quantity of the substance being determined. The percentage of the chromatographic signal does not necessarily correspond to the mass percentage of the peptide in the whole material.

In a mixture, it is also necessary to distinguish between the components. The dominant signal does not automatically represent the full characteristics of both substances or their proportions.

An article on the basics does not replace such documentation. Its purpose is to explain which structures and concepts are being discussed. Chemical data about a sample also remain separate from the assessment of its biological effects. The correct spelling of a name is not proof of safety, just as the result of a mass analysis is not a clinical trial.

Frequently asked questions

What is the difference between CJC-1295 and ipamorelin?

CJC-1295 and ipamorelin are different peptides. The former is a GHRH analogue, whereas ipamorelin is a pentapeptide acting on the ghrelin/GHS-R1a receptor. The common theme of growth hormone release does not mean an identical structure or the same onset of biological response. It is also necessary to check whether the name CJC-1295 in a given text refers to the structure with DAC or the material referred to as MOD-GRF (1–29). Without this, the comparison remains incomplete. The difference can be described by sequence, modifications and receptor, but not by a simple ranking of „stronger” or „safer”. Such a ranking would require indicating the measured parameter and direct comparative data. For someone starting to learn about the subject, the most important thing is to understand that two names mean two separate compounds. Their joint mention in an article or on a label does not create one new sequence and does not prove a specific outcome of their combination.

Do „CJC-1295 without DAC” and MOD-GRF (1–29) mean the same thing?

The name „CJC-1295 without DAC” is often used in reference to MOD-GRF (1–29), which is a modified 29-residue fragment of GHRH. However, this does not mean that the nomenclature in all publications and materials is consistent. Therefore, it is best to check the full sequence and description of the modification. It is particularly important to distinguish such material from the long-acting analogue featuring an albumin-binding moiety, studied as CJC-1295. The mere absence of the suffix in the title of an article does not make it possible to determine which structure was analysed. Nor should data on one of them be transferred to the other simply because they share a part of their name. For the reader, a practical rule of thumb is to treat the name as a starting point for identification rather than its final confirmation. In this article, the term MOD-GRF (1–29) has been used for the structure without DAC to help maintain this distinction.

What does DAC mean in simple terms?

DAC stands for the structural element of CJC-1295 related to the possibility of attaching the peptide to albumin. It is not an additional hormone or a standard solvent ingredient. In the full structural description, it must be taken into account that this is a chemically introduced fragment which distinguishes the analogue from the 29-residue structure without this element. Nor does the abbreviation mean on its own that the material is resistant to all degradation processes or that it has a better safety profile. It is the name of a specific chemical solution. The effect on the behaviour of the compound is assessed in studies, and not solely on the basis of the affix. The most important thing for the reader is to recognise that the presence of DAC changes the subject of the description. A result concerning a structure equipped with this element is not automatically a result for MOD-GRF (1–29). This applies both to the parameters of the substance's presence in the organism and to the interpretation of the subsequent hormonal response.

Is CJC-1295 with DAC simply a mixture of peptide and albumin?

The description of CJC-1295 with DAC does not mean a simple combination of two names on the ingredient list. It refers to an analogue featuring an element that enables a chemical bond to be formed with albumin. A distinction must be made between the analogue itself, the protein, and the resulting conjugate. The mere co-occurrence of the peptide and albumin is not yet the same as demonstrating their binding. In research, such a distinction can be significant for the interpretation of the signal and the substance's pharmacokinetic profile. Nor should the entire conjugate simply be called the free peptide if a different entity was analysed. For the non-specialist, it suffices to remember that a mixture and a compound formed by chemical attachment are different situations. The first indicates the presence of components alongside one another, while the second indicates a specific linkage. This distinction helps to understand DAC without assuming that albumin is an additional amino acid in the base sequence or a substitute for the name CJC-1295.

How many amino acid residues does MOD-GRF (1–29) contain?

MOD-GRF (1–29) contains 29 amino acid residues. The numbers in the name refer to the fragment that serves as the reference point for its structure, rather than the amount of material or duration of action. In the correct notation, two consecutive leucines appear at positions 22 and 23. Omission of one of them yields a different sequence, so it is not a minor stylistic difference. When counting, the prefix D at alanine should not be treated as an additional residue, nor should the terminal NH₂ be counted as an amino acid. Such designations represent other structural features. It is also worth remembering that an identical number of residues is not sufficient to establish the identity of two peptides. Their order, configuration, and terminals matter. In the case of CJC-1295 with DAC, the full description includes an additional structural element and should not be replaced by the 29-residue core sequence alone without modification.

Why is ipamorelin called a pentapeptide?

Ipamorelin is a pentapeptide because its chain comprises five residues: Aib, His, D-2-Nal, D-Phe and Lys. The prefix penta refers to the number five. It does not mean five separate substances present in a mixture. The residues are linked in a specific order, and the NH₂ terminus completes the description of the molecule. Small length alone is not evidence of weak action, easy penetration into every tissue, or safety. Such properties require separate data. A pentapeptide is a structural category, not an evaluation of suitability. There are also other five-residue peptides with a different structure, so the number of residues does not allow them to be equated with ipamorelin. For an accurate comparison, the full residue names, spatial designations and chain terminus must be retained. Thanks to this, the description remains unambiguous, even when different sources use slightly different ways of writing the same abbreviations.

What do Aib and D-2-Nal mean in the ipamorelin sequence?

Aib and D-2-Nal describe specific amino acid residues. Aib refers to α-aminoisobutyric acid, whereas D-2-Nal refers to the corresponding configuration of 2-naphthylalanine. These are neither names of additional products nor quantity designations. Their presence shows that the ipamorelin sequence does not consist solely of standard residues known from basic protein notation. However, one should not derive an independent safety assessment from this. Specifying the type of amino acid presents the structure. Similarly, the letter D does not mean that an additional aspartic acid appears in the chain; here, it acts as a configuration designator. The reader does not need to know all the chemical details of these residues to understand the article. It is important to retain their full notation when comparing materials. Replacing an unusual residue with another amino acid or removing the D designation alters the structural information and may lead to the erroneous identification of distinct peptides.

Do the D and L designations change the number of amino acids?

The designations D and L do not change the number of residues in the chain. They inform about the spatial configuration of a specific amino acid. D-Ala is a single residue, just like D-Phe. The prefix should not be separated from the name and counted as a separate sequence element. The spatial difference may be important for interaction with enzymes or receptors, but it does not determine the direction of all property changes by itself. In texts about MOD-GRF (1–29) and ipamorelin, the preservation of these designations is necessary for an accurate description. It is not always possible to replace them with a simple single-letter string without additional explanation. The molecular mass also does not determine this feature on its own, because different configurations can have the same elemental composition. For this reason, the sequence, configuration, and mass are related pieces of information, but none of them should be presented as a full replacement for all the others.

Is ipamorelin a fragment of GHRH?

Ipamorelin is not simply a shortened fragment of GHRH. It has its own five-residue sequence and is described in relation to the ghrelin/GHS-R1a receptor. In contrast, MOD-GRF (1–29) and CJC-1295 are structurally related to GHRH. Similar interest in GH release does not mean a common origin for every part of their structure. This is an important example of the difference between classification by structure and classification by observed response. Two compounds can participate in the regulation of the same hormone and yet belong to different receptor groups and have completely different sequences. Therefore, one should not reconstruct the structure of ipamorelin based on the name GHRH, nor transfer all the characteristics of its analogues to it. For comparison, it is enough to indicate the receptor, sequence and type of study. This information is more precise than broadly defining all substances as a single type of hormonal peptide.

Does selectivity mean the absence of adverse effects?

Selectivity is not a synonym for the absence of adverse effects. It describes the preference of a specific action relative to other responses evaluated under given conditions. In the case of ipamorelin, the term derives from studies involving the release of GH and selected other hormones. It does not mean that every biological process has been tested in all possible situations. It should not, therefore, be turned into an assurance that the substance does not affect anything other than growth hormone. Furthermore, targeting a specific receptor does not rule out various downstream consequences. Safety assessment involves other questions and requires appropriate data. In an educational article, the term selectivity can be retained, but its scope must be defined. Such an explanation allows the property to be described without overextending the conclusion. The reader then receives information about the nature of the studied action, rather than an unjustified promise of complete neutrality towards the rest of the organism.

Does an increase in GH or IGF-1 confirm an increase in strength or an improvement in sleep?

The increase in GH or IGF-1 concentration is a hormonal outcome. It does not constitute a direct measurement of muscle strength or sleep quality. Even if a biological link exists between a given hormone and a process in the body, assessing a specific result requires an appropriate method. Strength is measured differently than blood concentration, and sleep requires a different type of observation. In studies on CJC-1295 or ipamorelin, it is therefore necessary to check which parameters were actually evaluated. One should not attribute a whole catalogue of consequences to a hormonal result just because they sound consistent with the general description of the role of GH. Such an extension blurs the boundary between mechanism and evidence. A reliable text can explain why researchers are interested in a specific system, but it should present what has been demonstrated separately. The value of a study does not depend on the number of benefits attributed to it in a popular summary.

Does pulsatile secretion mean unchanged hormonal regulation?

The presence of secretion pulses does not mean that the entire hormonal profile has remained unchanged. Their frequency, amplitude, inter-pulse level and total response over time can be analysed. One of these parameters may change differently from the others. Therefore, the statement that pulsatility was still observed in the CJC-1295 study should not be replaced by an assurance that the system is completely intact. Similarly, a single GH result does not allow the entire course of secretion to be reconstructed. A series of measurements and an appropriate method of analysis are required. The word natural is sometimes unclear in this context, as it can simultaneously suggest the origin of the hormone, the secretion pattern and safety. These are different issues. It is clearer to name the parameter that was assessed and present its result. Thanks to this, the description retains the meaning of the study without attributing to it a general guarantee of the correctness of all regulatory mechanisms.

Does the CJC-1295 research confirm the efficacy of the mixture with ipamorelin?

Studying CJC-1295 alone is not a study of its mixture with ipamorelin. It concerns a specific substance, population and conditions. Adding a second ingredient creates a different research question, even if there are separate publications for each ingredient. Furthermore, the presence of DAC should be checked, as a mixture described by an imprecise name may contain a structure other than that studied in the cited work. One cannot simply sum up the conclusions from two articles and assume that the full set of benefits of the combination has been demonstrated. Different receptors provide a premise for formulating hypotheses, but they do not replace comparison. In a neutral text, it is therefore worth separating knowledge about the ingredients from knowledge about the entire system. This does not imply in advance either the effectiveness or the lack of activity of the mixture. It merely means that its properties require data concerning this exact combination, rather than similarly sounding names.

Do two different receptors automatically mean synergy?

Acting on two different receptors does not automatically prove synergy. Synergy requires defining the expected response and comparing it with the result for the combination. One needs to know what was measured and how each component behaved individually. With regard to CJC-1295 and ipamorelin, merely listing GHRH-R and GHS-R1a is not yet the result of such an analysis. Nor should a stronger signal in a single measurement be treated as proof of broader clinical benefits. Even if interaction regarding GH were demonstrated, separate questions would still remain concerning other outcomes and safety. In the article, therefore, the word synergy should indicate a specific result or a clearly named hypothesis. Using it as a general term for an attractive combination makes it difficult for the reader to evaluate the evidence. Most helpful is a clear separation of a possible biological explanation from an actually performed comparative study.

Does a shorter half-life mean a lower risk?

A shorter half-life describes only one aspect of a substance's presence in the body. It is not a complete risk assessment. It does not independently determine the strength of the response, all previously triggered processes, or the behaviour of the material in every population. Therefore, comparisons of CJC-1295 with DAC and MOD-GRF (1–29) should not lead to the conclusion that a shorter time always means greater safety. Similarly, it cannot be used to guarantee preserved insulin sensitivity or the absence of an excessive hormonal response. These issues require separate data. A peptide's half-life must also be distinguished from the timing of changes in selected hormones. These do not necessarily run identically. For a general article, the most important thing is to explain the significance of the parameter without turning it into a safety ranking or a guide to use. A single number can help describe a study, but it cannot replace the full biological characterisation of a compound or mixture.

Can the result obtained in an animal be directly applied to a human?

The result obtained in an animal describes the applied model and experiment conditions. It may be important for understanding the mechanism, but it does not automatically confirm an analogous result in humans. In the case of CJC-1295 and ipamorelin, attention should be paid not only to the species, but also to age, baseline condition and the evaluated tissue. Studying an organism with an intentionally introduced disorder answers a different question than observing a healthy population. Yet another level is an experiment on isolated tissue. These categories should not be combined into a general statement about the effect in all individuals. The value of a preclinical observation can be preserved by indicating its scope and not anticipating further research. Such a description is more precise than assuring of a clinical benefit based solely on the similarity of the hormone name or process between species. The model helps to study the question, but it does not eliminate biological differences.

Does the acetate form change the peptide sequence?

The information about the acetate form alone does not imply a rearrangement or substitution of amino acid residues. It relates to the chemical form of the material, which must be distinguished from the primary sequence. In the case of CJC-1295, the presence of DAC must also be checked, because the acetate and the albumin-binding moiety do not mean the same thing. Also for ipamorelin, the formula of the peptide unit alone is not automatically a full description of the entire sample containing counterions and water. When comparing masses or content, the basis of the presented result is important. One should not assume that every number refers to an identically defined material. For a non-specialist, it is sufficient to separate the order of residues, the additional modification of the molecule, and the composition of the whole sample. This makes it possible to read names correctly without assigning the meaning of a new peptide to each suffix. At the same time, the name of the salt alone does not confirm all the properties or the quality of a specific batch.

How to recognise a reliable source of information about these peptides?

A reliable source makes it possible to determine what relationship was studied, in which population and using what measurements. In the case of CJC-1295, the presence or absence of DAC is particularly important. With ipamorelin, a distinction must be made between hormonal studies and other clinical or experimental questions. It is worth checking whether the author is presenting their own data, describing someone else's publication, analysing internet discussions or posting commercial content. A link to a document alone does not prove that it supports all neighbouring claims. Likewise, the place of publication of a document does not determine its authorship. A good description preserves the limitations of the study, does not turn a statistically non-significant result into proven efficacy, and does not transfer the results of a single ingredient to the entire mixture. It does not have to be written in difficult language. Above all, it should clearly separate structure, mechanism, observed result and the conclusion that can actually be drawn from it.

Disclaimer

The article is educational in nature and concerns the nomenclature, structure, and basics of interpreting research on CJC-1295, MOD-GRF (1–29), and ipamorelin. It does not constitute medical advice, a purchase recommendation, or instructions for preparing, dosing, combining, or administering substances. The description of the sequence and hormonal response does not confirm the safety or suitability of any material for human use. The cited 2024 FDA documents were used as sources for the characteristics and differentiation of the substances, rather than as a current review of the law in individual countries or confirmation of product approval. It is important to note that the article concerns substances in general – it is not a description of a specific product (chemical reagent).

References

1. Jetté, L., Léger, R., Thibaudeau, K., et al. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058. Source regarding the construction of CJC-1295 and albumin binding. PubMed. DOI.
2. US Food and Drug Administration. FDA Briefing Document: CJC-1295-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, 4 December 2024. Utilised structural characteristics, sequence and the differentiation of forms with and without DAC. FDA document.
3. Raun, K., Hansen, B. S., Johansen, N. L., et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561. Source regarding the sequence and experimental characterisation of ipamorelin. DOI.
4. U.S. Food and Drug Administration. FDA Briefing Document: Ipamorelin-Related Bulk Drug Substances. Pharmacy Compounding Advisory Committee, 29 October 2024. The chemical characteristics of ipamorelin and its salt forms were utilised. FDA document.
5. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analogue of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805. PubMed. DOI.
6. Ionescu, M., Frohman, L. A. (2006). Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analogue. The Journal of Clinical Endocrinology & Metabolism, 91(12), 4792–4797. Publication page.
7. Gobburu, J. V., Agersø, H., Jusko, W. J., Ynddal, L. (1999). Pharmacokinetic-pharmacodynamic modelling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharmaceutical Research, 16(9), 1412–1416. PubMed. DOI.
8. Beck, D. E., Sweeney, W. B., McCarter, M. D., Ipamorelin 201 Study Group. (2014). Prospective, randomised, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. International Journal of Colorectal Disease, 29(12), 1527–1534. PubMed. DOI.